Recently added

Cetuximab every 2 weeks versus standard weekly dosing administration schedule

Bokemeyer, Carsten; Dubreuil , Olivier; GUIGAY, Joel; Kasper, Stefan; Pfeiffer, Per; Ciardiello, Fortunato; Tabernero, Josep (Future Medicine, 2024-03)

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial

Haakensen, Vilde Drageset; Öjlert, Åsa Kristina; Farooqi, Saima Jamil; Nowak, Anna; Chin, Wee L.; cedres, susana; Thunold, Solfrid (Elsevier, 2024-03-01)

Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study

Griesinger, Frank; Baik, Christina; Tan, Daniel; Lee, Dae Ho; Curigliano, Giuseppe; Subbiah, Vivek; GARRALDA, Elena (Future Medicine, 2024-02)

Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases

Bermejo-Pelaez, David; Rueda Charro, Sandra; García Roa, María; Trelles-Martinez, Roberto-Oswaldo; Bobes-Fernández, Alejandro; Hidalgo Soto, Marta (Oxford University Press, 2024-02)

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

Villacampa Javierre, Guillermo; Pascual, Tomás; Brasó Maristany, Fara; Paré, Laia; Martínez-Sáez, Olga; Cortes, Javier (Elsevier, 2024-03-04)

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

Cetuximab every 2 weeks versus standard weekly dosing administration schedule

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial

Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study

Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

Cetuximab every 2 weeks versus standard weekly dosing administration schedule ﻿

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial ﻿

Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study ﻿

Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases ﻿

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B) ﻿

Cetuximab every 2 weeks versus standard weekly dosing administration schedule

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial

Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study

Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)